Arbutus Biopharma
phase a clinical trial with | Arbutus Biopharma
Company
Deck Type
Sector
Industry
Deck date
June 2024
Slide
23 of 26
Similar slides by Arbutus Biopharma
See diffirences between slides (animation)
Investor Presentation
January 2024
phase a clinical trial with | Arbutus Biopharma
Investor Presentation
November 2023
phase a clinical trial with | Arbutus Biopharma
Related slides by other companies
Larimar Therapeutics
Results
November 2022
study design | Larimar Therapeutics
BioNTech
Results
March 2022
phase expansion cohorts ongoing | BioNTech
Larimar Therapeutics
Investor Presentation
November 2023
phase dose exploration study for and cohorts | Larimar Therapeutics
Enochian Biosciences
Investor Presentation
January 2024
initial clinical study phase i open to all solid tumors focus on patients with pancreatic cancer phase i safety assessment ascending dose ranging cohort of up to patients dose level phase enrollment starting in late fixed dose cohort design one cohort cancer type assumes high response rate up to patients extending cohort into assuming responding tumor type seek breakthrough and or designation for accelerated development and approval data to support available end first half of | Enochian Biosciences
Other recent decks by Arbutus Biopharma
See all presentations (8 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
October 2023
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights